

Amendments to the Claims:

Please cancel claims 19-24 and 35-40. This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-8. Canceled.

9. (Previously presented) A method of inhibiting progression in a patient of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, comprising administering to said patient an effective amount of an inhibitor of soluble epoxide hydrolase (“sEH”).

10. (Previously presented) A method of claim 9, wherein the obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease (“COPD”), emphysema, and chronic bronchitis.

11. (Withdrawn) A method of claim 9, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

12. (Withdrawn) A method of claim 9, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

13. (Withdrawn) A method of claim 9, wherein the condition is asthma.

14. (Previously presented) A method of claim 9, wherein said inhibitor of sEH is selected from the group consisting of an adamantyl dodecyl urea, N-cyclohexyl-N'-dodecyl urea (CDU) and N, N'-dicyclohexylurea (DCU).

15. (Previously presented) A method of claim 9, wherein the inhibitor is in a slow release formulation.

16. (Previously presented) A method of claim 9, further comprising administering a *cis*-epoxyeicosantrienoic acid (“EET”).
17. (Previously presented) A method of claim 9, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.
18. (Previously presented) A method of claim 9, wherein said EET is 14R,15S-EET.
- 19-24. (Canceled)
25. (Original) A method of inhibiting progression of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, said method comprising administering an inhibitor of soluble epoxide hydrolase (“sEH”) and a *cis*-epoxyeicosantrienoic acid (“EET”) to a person in need thereof.
26. (Original) A method of claim 25, wherein said obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease (“COPD”), emphysema, and chronic bronchitis.
27. (Withdrawn) A method of claim 25, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.
28. (Withdrawn) A method of claim 25, wherein the interstitial lung disease is one associated with occupational exposure to a dust.
29. (Withdrawn) A method of claim 25, wherein the condition is asthma.
30. (Original) A method of claim 25, wherein the inhibitor of sEH or the EET, or both, is in a material which releases the inhibitor over time.
31. (Original) A method of claim 25, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.

32. (Original) A method of claim 25, wherein said EET is 14R,15S-EET.
33. (Original) A method of claim 25, wherein the inhibitor is administered orally.
34. (Original) A method of claim 25, wherein the inhibitor is administered in a total daily dose from about 0.001 mg/kg to about 100 mg/kg body weight.
- 35-40. (Canceled)
41. (Withdrawn) A method of reducing infiltration of neutrophils into a lung of a patient suffering from a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, comprising administering to said patient an effective amount of an inhibitor of soluble epoxide hydrolase (“sEH”).
42. (Withdrawn) A method of claim 41, wherein the obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease (“COPD”), emphysema, and chronic bronchitis.
43. (Withdrawn) A method of claim 41, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.
44. (Withdrawn) A method of claim 41, wherein the interstitial lung disease is one associated with occupational exposure to a dust.
45. (Withdrawn) A method of claim 41, wherein the condition is asthma.
46. (Withdrawn) A method of claim 41, wherein said inhibitor of sEH is selected from the group consisting of an adamantyl dodecyl urea, N-cyclohexyl-N'-dodecyl urea (CDU) and N, N'-dicyclohexylurea (DCU).
47. (Withdrawn) A method of claim 41, wherein the inhibitor is in a slow release formulation.

48. (Withdrawn) A method of claim 41, further comprising administering a cis-epoxyeicosantrienoic acid (“EET”).

49. (Withdrawn) A method of claim 41, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.

50. (Withdrawn) A method of claim 41, wherein said EET is 14R,15S-EET.